Sign in
Immunologynpj Vaccines
Peer-reviewed journal article

Enhanced immunogenicity of a Clostridioides difficile TcdB vaccine adjuvanted with a synthetic dual-TLR ligand adjuvant.

Farha NaziD, Nicholas Hagspiel, Feifan Xu, Brandon A. ThompsoniD, G. Brett MoreauiD, Mary Young, Joel F. Herbein, Christopher B. FoxiD, William A. PetriiD, Mayuresh M. Abhyankar

Abstract

We report a comprehensive evaluation of the toxin B (TcdB) vaccine adjuvanted with a dual Toll-like receptor ligand liposome adjuvant for Clostridioides difficile infection (CDI). The vaccine completely protected mice from a lethal infection. Compared to alum adjuvanted TcdB, it generated functionally superior systemic antibodies and supported strong memory B cell and gut IgA responses. This pharmaceutically acceptable adjuvant platform holds promise for developing a next-generation CDI vaccine.

PDFDOI

02 /Specification & Classification

Click any tag to browse matching papers

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISWang '26Maslanka '25Lee '20Maia '20Alugupalli '24Maslanka '26
74% semantic matchMicrobiology
Shaohui Wang, Joshua Heuler, Yukihiro Nakanishi+2 more·bioRxiv·Aug 31, 2026